Companies - Kiadis Pharma

Price

 
Price
€ 7,66
Change
€ -0,41
Change %
-4,97%
Open
€ 8,25
High
€ 8,30
Low
€ 7,61
Volume
401.036

Profile

 
Profile
Kiadis Pharma is a pharmaceutical company in the clinical development stage focused on research, development and future commercialization of cellular immunotherapy products for the treatment of blood cancers and inherited blood diseases.
Industry
Biotechnology
Description
Companies in the biotechnology industry are performing research and development activities for the purpose of discovering new drugs and diagnostics. The turnover of these companies comes from sales of these products or the sale of licenses of drugs and diagnostic to other companies.

Key figures (2016)

 
The ratios below are calculated using the last known share price and the last known company financials.

Ratios per share

Price to Earnings
-7,124
Price to Earnings (3 years)
-8,092
Price to Earnings (5 years)
-10,012
Price to earnings growth
-
Price/cashflow
-7,197
Price/net cashflow
-7,457
Price/book value
11,161
Price to sales
-

Ratios for dividend

Dividend yield
-
Pay out
-

Valuation ratios

Market value/PE
11,161
Market value/turnover
-
Enterprise value/turnover
-

Return ratios

Return on private equity
-156,67%
Return on total equity
-50,62%
Profit margin
-

Risk ratios

Solvability
0,323
Solvability
1,477
Current ratio
3,631
Debt to Equity
2,095

Value invest ratios

Grahams Number
€ -0,34
Grahams Value
€ -8,00
Grahams Product
-79,513
Grahams Product (3 years)
-90,322

2016

 

Profit and loss

Net profit (x 1 mln)
€ -14,79
Turnover (x 1 mln)
-
Cashflow(x 1 mln)
€ -14,64
Net cashflow(x 1 mln)
€ -14,13

Balance

Private equity (x 1 mln)
€ 9,44
Foreign equity (x 1 mln)
€ 19,78
Current assets (x 1 mln)
€ 15,14
Current liabilities (x 1 mln)
€ 4,17
Working capital (x 1 mln)
€ 10,97
Balance total (x 1 mln)
€ 29,22

Share

Outstanding shares (x 1 mln)
13,755
Price year-end
€ 8,45
Dividend per share
-
Earnings per share
€ -1,08
Cashflow per share
€ -1,06
Net cashflow per share
€ -1,03
Book value per share
€ 0,69
Stockmarket value (x 1 mln)
€ 116,27

History

 
Year
2016
2015
2014
2013
2012
Net profit (x 1 mln)
€ -14,79
€ -16,46
€ -7,81
€ -6,89
€ -6,67
Turnover (x 1 mln)
-
-
-
-
-
Price year-end
€ 8,45
€ 12,26
-
-
-
Year high
€ 12,50
€ 12,85
-
-
-
Year low
€ 6,93
€ 10,55
-
-
-
Outstanding shares (x 1 mln)
13,755
12,057
10,471
10,896
9,853
Price to Earnings
-7,861
-8,977
-
-
-
Earnings per share
€ -1,08
€ -1,37
€ -0,75
€ -0,63
€ -0,68
Dividends
-
-
-
-
-
Dividend yield
-
-
-
-
-
Pay out
-
-
-
-
-
Private equity (x 1 mln)
€ 9,44
€ 25,65
€ 2,67
€ 5,36
€ 12,51
PE per share
€ 0,69
€ 2,13
€ 0,25
€ 0,49
€ 1,27
Balance total (x 1 mln)
€ 29,22
€ 42,28
€ 20,21
€ 20,19
€ 25,43
Stockmarket value (x 1 mln)
€ 116,27
€ 147,76
-
-
-

Company analysis

 

Analysis of profit indicators

Average profit per share (4 years)
€ -1,12
Standard deviation average profit
€ 0,40 (-35,73%)
Average annual growth rate
-14,71%
Compound annual growth percentage
-19,90%